13F-HR filed by Omega Fund Management, LLC
Omega Fund Management, LLC filed this 13F-HR for the quarter ended 2026-09-30, accepted by EDGAR 2026-11-16 13:00:05 UTC, with 10 holding rows worth $125,163,396.
- Accession
- 0001193125-26-462150
- Filer
- CIK 1637359
- Filed
- 2026-11-16
- Accepted by EDGAR
- Ingested
- Source
- EDGAR live feed
13F report for Q3 2026
A holdings report, 10 entries on the cover page, a total value of $125,163,396 stated on the cover page (in dollars after the unit check, H1), rows summing to $125,163,395 with VALUE read as dollars as filed, 13F file number 028-16844. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| NUVATION BIO INC COM CL A | 67080N101 | Stock | 7,151,031 | $40,045,774 | dollars as filed | |
| BICARA THERAPEUTICS INC | 055477103 | COM | 1,759,912 | $32,751,962 | dollars as filed | |
| BETA BIONICS INC | 08659B102 | COMMON STOCK | 962,010 | $18,258,950 | dollars as filed | |
| BRIDGEBIO ONCOLOGY THERAPEUT | 107924102 | COM NEW | 3,289,661 | $13,487,610 | dollars as filed | |
| KESTRA MED TECHNOLOGIES LTD | G52441105 | SHS | 362,394 | $10,252,126 | dollars as filed | |
| IMMUNIC INC | 4525EP200 | COM NEW | 430,180 | $4,000,674 | dollars as filed | |
| SANA BIOTECHNOLOGY INC | 799566104 | COM | 843,750 | $2,463,750 | dollars as filed | |
| IMAGENEBIO INC | 45175G207 | CMN | 455,361 | $2,085,553 | dollars as filed | |
| ENGENE HOLDINGS INC | 29286M105 | COM | 876,357 | $1,752,714 | dollars as filed | |
| Odyssey Therapeutics, Inc. | 67613T104 | COMMON STOCK | 2,893 | $64,282 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001193125-26-462150 | this filing | 2026-11-16 |